Log in

NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

$14.70
-0.84 (-5.41 %)
(As of 04/2/2020 07:18 AM ET)
Today's Range
$14.38
Now: $14.70
$15.53
50-Day Range
$12.50
MA: $16.90
$22.04
52-Week Range
$11.05
Now: $14.70
$31.50
Volume211,957 shs
Average Volume322,235 shs
Market Capitalization$664.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.29
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle, and eye in gene editing and gene therapy modalities. Its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Read More
Homology Medicines logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$5.73 per share

Profitability

Net Income$-103,920,000.00
Net Margins-6,237.46%

Miscellaneous

Employees124
Market Cap$664.44 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.


Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

How has Homology Medicines' stock been impacted by COVID-19 (Coronavirus)?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FIXX stock has decreased by 17.9% and is now trading at $14.70. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Homology Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Homology Medicines.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Homology Medicines.

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) posted its quarterly earnings data on Thursday, March, 12th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.13. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.40 million. Homology Medicines had a negative return on equity of 42.62% and a negative net margin of 6,237.46%. View Homology Medicines' earnings history.

What price target have analysts set for FIXX?

7 brokerages have issued 1-year target prices for Homology Medicines' shares. Their forecasts range from $29.00 to $37.00. On average, they anticipate Homology Medicines' share price to reach $33.33 in the next twelve months. This suggests a possible upside of 126.8% from the stock's current price. View analysts' price targets for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

News headlines about FIXX stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Homology Medicines earned a news impact score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutHomology Medicines.

Are investors shorting Homology Medicines?

Homology Medicines saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,588,300 shares, a drop of 5.3% from the February 27th total of 3,790,000 shares. Based on an average trading volume of 366,500 shares, the days-to-cover ratio is currently 9.8 days. Currently, 17.1% of the shares of the company are sold short. View Homology Medicines' Current Options Chain.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Inovio Pharmaceuticals (INO), Bank of America (BAC), Heron Therapeutics (HRTX), Stag Industrial (STAG), Gossamer Bio (GOSS), Nektar Therapeutics (NKTR) and Novavax (NVAX).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $14.70.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $664.44 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 124 workers across the globe. View additional information about Homology Medicines.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com/.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel